Gadolinium-Based MRI Contrast Agents Linked To Hypersensitivity Reactions: Study

Severe gadolinium-based contrast agent reactions could include heart rhythm problems and anaphylactic shock, researchers warn.

Exposure to gadolinium-based contrast agents (GBCAs) that are used to improve the magnetic resonance imaging (MRI) scans may place patients at risk for allergic-like hypersensitivity reactions, according to the findings of a new study.

Korean researchers say about one out of every 250 patients who receives a gadolinium contrast agent before undergoing an MRI scan suffers hypersensitivity reactions, with most of the cases being acute. Their findings were published online on February 22 in the medical journal Radiology.

Gadolinium contrast agents are commonly used during an MRI exam to improve the imaging and help doctors see abnormal tissue with more detail. The toxic metal used in the contrast dye is supposed to safely pass through the body for individuals without impaired kidney function, but there have been concerns in recent years about the potential risks associated with gadolinium deposits found in the brain for some users.

In this new study, researchers looked at all cases of hypersensitivity reactions to MRI contrast agents, which occurred at the Seoul National University Hospital between July 1, 2012 and June 30, 2020.

Researchers found 1,304 cases of hypersensitivity reactions (HSRs) out of 331,070 GBCA exposures in 154,539 patients. Those cases represent about 0.4% of exposures, and of those 1,178 were considered acute reactions. In a small number of those cases, the reactions were delayed, not appearing until a significant time after exposure. The risk of hypersensitivity reactions linked to GBCAs was more than four times higher than the risk associated with iodine-based contrast agents, the researchers determined.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Mild reactions to the MRI contrast included throat discomfort, nasal congestion, sneezing and rhinorrhea, as well as limited urticaria and pruritus. Moderate reactions included mild wheezing, bronchospasm, hoarseness, facial edema, diffuse urticaria and pruritus and diffuse erythema. Severe reactions included life threatening symptoms including diffuse edema with dyspnea, diffuse erythema with hypotension, laryngeal edema with stridor or hypoxia, wheezing or broncospasms with hypoxia, symptomatic arrhythmias and anaphylactic shock.

However, researchers found that premedication with drugs used to treat such reactions, changing to a different type of contrast agent, appeared to significantly reduce the risk of patients developing hypersensitivity reactions, particularly in those patients with a history of delated allergic reactions.

“In conclusion, acute and delayed hypersensitivity reactions (HSRs) were observed in 0.4% and 0.04% of patients exposed to gadolinium-based contrast agents (GBCAs), respectively,” the researchers noted. “In all patients undergoing MRI with GBCA exposure, a detailed history of previous HSRs should be conducted, and when necessary, appropriate prevention measures such as using premedication and switching to a different type of GBCA should be implemented.”

Gadolinium Contrast Agent Side Effects

In December 2017, the FDA issued a drug safety communication for certain types of contrast agents, providing new information about the risk of gadolinium retention and potential side effects. As a result, manufacturers were required to provide new warnings and information in a Medication Guide, which all patients receiving an MRI contrast dye will be asked to read.

The FDA also recommended that health care professionals consider the fact that the body retains gadolinium when deciding whether to give it to patients that may be at higher risk of health problems. These include women who are pregnant or think they may be pregnant, patients with kidney problems, children, and patients when inflammatory conditions. The recommendations also suggest that repeated use of the contrast agents be minimized where possible, particularly when MRIs are scheduled closely together.

Patients are now urged to tell their health care professionals whether they are pregnant or may be pregnant, whether they have kidney problems, and the date of their last MRI with gadolinium, or whether they have had repeated MRI scans that involved the use of gadolinium contrast agents.

In recent years, there have also been growing concerns about the risk of gadolinium deposition disease, involving complaints of pain, brain fog and other symptoms experienced among individuals without kidney impairment, who have been found with an accumulation of the metal remaining in their body after an MRI exam.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court
First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court (Posted yesterday)

The first Gardasil lawsuit will go to trial in California state court in October, as a group of cases at the federal level continue to be developed for future bellwether trials that are unlikely to begin until late 2025 or early 2026.

Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month
Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month (Posted yesterday)

Parties have been directed to meet quarterly for mediation sessions, which will explore the potential for Tepezza hearing loss settlements, as the talks leading up to the first bellwether trials, slated to begin in March 2026.